Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Cytos Biotechnology has initiated the process of liquidating itself following the failure of its lead product candidate, CYT003, an asthma treatment in Phase II clinical trials. Cytos, which currently has 36 employees, underwent a significant downsizing in 2011, dropping other early-stage development projects and reducing staff from 82 to 10 workers. The company’s cash balance as of March 31 was $35 million.
This article has been sent to the following recipient: